Literature DB >> 25421584

Viral hepatitis: cure of chronic hepatitis C--required length of follow-up?

Peter Ferenci1.   

Abstract

The best time point to determine cure of chronic hepatitis C was explored in a retrospective analysis of five published trials of sofosbuvir–ribavirin with or without PEG-IFN. The authors conclude that SVR12 can be used effectively to determine ‘cure’ rates in trials and in clinical practice.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25421584     DOI： 10.1038/nrgastro.2014.198

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  10 in total

1.  Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.

Authors:  Michelle Martinot-Peignoux; Christiane Stern; Sarah Maylin; Marie-Pierre Ripault; Nathalie Boyer; Laurence Leclere; Corinne Castelnau; Nathalie Giuily; Ahmed El Ray; Ana-Carolina Cardoso; Rami Moucari; Tarik Asselah; Patrick Marcellin
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

2.  Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.

Authors:  Isabel Campos-Varela; Lluis Castells; Juan Ignacio Esteban; Marta Bes; Francisco Rodríguez-Frías; Gonzalo Sapisochin; Helena Allende; Ramón Charco; Rafael Esteban
Journal:  Transplantation       Date:  2012-02-27       Impact factor: 4.939

3.  Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.

Authors:  Eric M Yoshida; Mark S Sulkowski; Edward J Gane; Robert W Herring; Vlad Ratziu; Xiao Ding; Jing Wang; Shu-Min Chuang; Julie Ma; John McNally; Luisa M Stamm; Diana M Brainard; William T Symonds; John G McHutchison; Kimberly L Beavers; Ira M Jacobson; K Rajender Reddy; Eric Lawitz
Journal:  Hepatology       Date:  2014-11-24       Impact factor: 17.425

4.  Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus.

Authors:  Sandra Beinhardt; Karoline Rutter; Albert Friedrich Stättermayer; Peter Ferenci
Journal:  Clin Infect Dis       Date:  2012-09-28       Impact factor: 9.079

5.  Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

Authors:  Stefan Zeuzem; Geoffrey M Dusheiko; Riina Salupere; Alessandra Mangia; Robert Flisiak; Robert H Hyland; Ari Illeperuma; Evguenia Svarovskaia; Diana M Brainard; William T Symonds; G Mani Subramanian; John G McHutchison; Ola Weiland; Hendrik W Reesink; Peter Ferenci; Christophe Hézode; Rafael Esteban
Journal:  N Engl J Med       Date:  2014-05-04       Impact factor: 91.245

6.  A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.

Authors:  Mark G Swain; Ming-Yang Lai; Mitchell L Shiffman; W Graham E Cooksley; Stefan Zeuzem; Douglas T Dieterich; Armand Abergel; Mário G Pessôa; Amy Lin; Andreas Tietz; Edward V Connell; Moisés Diago
Journal:  Gastroenterology       Date:  2010-07-14       Impact factor: 22.682

7.  Twelve week post-treatment undetectable hepatitis C virus (HCV)-RNA by PCR assay predicts a sustained virological response to anti-HCV therapy independently from immunological status of the infected patients.

Authors:  Maria Francesca Donato; Anan Judina Bastiampillai; Matteo Manini; Sara Monico
Journal:  J Antimicrob Chemother       Date:  2012-12-05       Impact factor: 5.790

8.  Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral.

Authors:  K Rutter; H Hofer; S Beinhardt; M Dulic; M Gschwantler; A Maieron; H Laferl; A F Stättermayer; T-M Scherzer; R Strassl; H Holzmann; P Steindl-Munda; P Ferenci
Journal:  Aliment Pharmacol Ther       Date:  2013-05-26       Impact factor: 8.171

9.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

10.  Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

Authors:  Ira M Jacobson; Stuart C Gordon; Kris V Kowdley; Eric M Yoshida; Maribel Rodriguez-Torres; Mark S Sulkowski; Mitchell L Shiffman; Eric Lawitz; Gregory Everson; Michael Bennett; Eugene Schiff; M Tarek Al-Assi; G Mani Subramanian; Di An; Ming Lin; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Keyur Patel; Jordan Feld; Stephen Pianko; David R Nelson
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245
  10 in total
  2 in total

1.  Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV infection.

Authors:  Nikhil Pathak; Mei-Ling Lai; Wen-Yu Chen; Betty-Wu Hsieh; Guann-Yi Yu; Jinn-Moon Yang
Journal:  BMC Bioinformatics       Date:  2017-12-28       Impact factor: 3.169

2.  Ultrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome Predictors.

Authors:  Anna Rosa Garbuglia; Ubaldo Visco-Comandini; Raffaella Lionetti; Daniele Lapa; Filippo Castiglione; Gianpiero D'Offizi; Chiara Taibi; Marzia Montalbano; Maria Rosaria Capobianchi; Paola Paci
Journal:  PLoS One       Date:  2016-08-25       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.